Malignant Melanoma Clinical Trials

Birmingham : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Tucson : Call for Information (Investigational Site 0007) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Tucson :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Beverly Hills : Call for Information (Investigational Site 0061) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Encinitas : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

La Jolla : Moores UCSD Cancer Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

La Jolla :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Los Angeles : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

View More »

Los Angeles :

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Los Angeles :

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Los Angeles : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Los Angeles : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Los Angeles :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Los Angeles :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Los Angeles : Childrens Hospital Of La

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Los Angeles : Call for Information (Investigational Site 0018) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Los Angeles : Call for Information (Investigational Site 0034) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Los Angeles :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Orange : Children'S Hospital Of Orange County

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Orange : Chao Family Comprehensive Cancer Center

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Pleasant Hill : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

San Francisco : St Mary's Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

San Francisco : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Santa Monica : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Santa Monica :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Santa Rosa : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Aurora : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Aurora :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Aurora :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

New Haven : Yale University School Of Medicine

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Fort Myers : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Miami Beach : Mount Sinai Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Miami Beach : Call for Information (Investigational Site 0053) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Saint Petersburg : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

St. Petersburgh :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

View More »

Tampa :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Tampa :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Chicago : Rush University Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Chicago : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Niles : Oncology Specialists, SC

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Park Ridge : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Park Ridge :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Goshen : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Indianapolis : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Indianapolis : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Bethesda :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Boston :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Boston :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Boston : Dana-Farber Cancer Institute

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Detroit : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Detroit :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Rochester :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

St. Louis :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

St. Louis :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Las Vegas :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Morristown : Atlantic Melanoma Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Randolph : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Bronx : Montefiore Medical Center

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

New York : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

New York : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

New York :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

New York : Memorial Sloan Kettering Cancer Center

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

View More »

New York :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Charlotte :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Durham : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Durham : Call for Information (Investigational Site 0036) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Winston-salem : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Portland : Oregon Health and Science University

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Bethlehem : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Bethlehem : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Bethlehem : Call for Information (Investigational Site 0001) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Philadelphia : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Pittsburgh : University of Pittsburgh

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

View More »

Pittsburgh :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Memphis :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Memphis : St. Jude Children'S Research Hospital

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Nashville : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Nashville :

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Nashville : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

View More »

Nashville : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Nashville : Call for Information (Investigational Site 0033) Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Nashville :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Dallas : Mary Crowley Cancer Research Centers

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Dallas :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Dallas : Mary Crowley Cancer Research Center

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Dallas :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Dallas : Mary Crowley Cancer Research Center

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

View More »

Houston :

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Houston :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Houston : University of Texas MD Anderson Cancer Center

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Salt Lake : Huntsman Cancer Institute

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Salt Lake City : Huntsman Cancer Institute

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Seattle :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

East Melbourne :

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Frankston : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Gateshead : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Greenslopes : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Herston : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

View More »

Herston :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Hobart : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Kurralta Park : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Lismore : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Melbourne : Updated

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Melbourne :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

St Leonards : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Tiwi : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Wentworthville :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Westmead :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Innsbruck : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Wels : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Bruxelles : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bruxelles : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Hasselt : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Kortrijk : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Wilrijk : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Banja Luka : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Rio de Janeiro : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Sao Paulo : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Plovdiv : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Sofia : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Halifax : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Montreal : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Toronto : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Toronto :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Vancouver : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

View More »

Winnipeg : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Medellin : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Zagreb : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Brno : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Hradec Kralove : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Olomouc : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Praha : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Guayaquil : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Portoviejo : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Helsinki : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bordeaux :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Boulogne Billancourt :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Colmar :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Lille :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Lille :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

View More »

Lyon :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Marseille :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Montpellier :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Nantes :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Nice :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Paris :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Paris :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Pessac :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Rouen :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Vandoeuvre Les Nancy :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Villejuif :

Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples

Essen :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Frankfurt :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Freiburg : University Medical Center Freiburg, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Jena : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Kiel :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

View More »

Kiel :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Köln : University Medical Center Collogne, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Mainz :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Mannheim : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Mannheim :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Münster :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Tübingen :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Tuebingen :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Wiesbaden : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Athens : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Heraklion : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Hyderabad : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Lucknow : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Mumbai : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Nashik : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

New Delhi : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Trivandrum : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Vellore : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Cork : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Dublin : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Galway : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Limerick : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Waterford : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Hod Hasharon : Merck Sharp & Dohme Co. Ltd. Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Jerusalem : Oncology institute, Shaare Zedek Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel Hashomer : Oncology Institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel-hashomer :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Bari : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bergamo : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bergamo : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Firenze : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Genova : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Genova :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Meldola : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Milano : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Milano :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Milano :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Napoli : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Napoli : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Napoli : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Padova : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Pisa : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Roma : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Roma :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Siena : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Siena : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Siena :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Udine : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Tokyo : MSD K.K.

A Study of Pegylated Interferon Alfa-2b as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (P08556)

Seoul : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Klaipeda : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Vilnius : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Skopje : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Amsterdam :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Blaricum : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Breda : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Groningen : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Groningen :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

View More »

Haarlem : Merck Sharp & Dohme BV Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Maastricht : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bergen : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Drammen : MSD (Norge) AS Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Oslo : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Arequipa : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Timisoara : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bloemfontein : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Cape Town : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Johannesburg : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Pretoria : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Barcelona :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Cordoba : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Granada : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

La Coruna : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

La Laguna (tenerife) : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Leon : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Madrid : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Madrid :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Madrid : Merck Sharp and Dohme de Espana S.A. Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Malaga : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Pamplona :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Valencia : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Zaragoza : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Jönköping : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Lund : Lunds Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Sollentuna : MSD Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Stockholm : Karolinska Sjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Stockholm : Södersjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

View More »

Umeå : Norrlands Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Glattbrugg : MSD Merck Sharp & Dohme AG Updated

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Adana : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Ankara : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Antalya : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bornova, Zmr : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Gaziantep : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Istanbul : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Izmir : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Shhiye, Ankara : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Birmingham : Queen Elizabeth Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Cambridge : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Cambridge : Addenbrooke's Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Edinburgh : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Glasgow : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Glasgow : The Beatson Institute

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Leeds : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Leeds : St James' Institute of Oncology

Study of a DNA Immunotherapy to Treat Melanoma

Leeds : St James Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

London : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Manchester : Christie Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Newcastle Upon Tyne : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Newcastle Upon Tyne :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Northwood : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Northwood :

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Nottingham : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Nottingham : Department of Clinical Oncology, City Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Oxford : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Oxford : Updated

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Oxford : NIHR Biomedical Research Centre

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Southampton : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Southampton : Department of Medical Oncology, Southampton General Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Sutton :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Swansea : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma